Tereza Cervenka, MD
NPI 1508087511 · Pulmonary Disease Physician · Minneapolis, MN
Enrolled with Medicare as Practitioner - Internal Medicine · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1508087511
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- 44419 (MN)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure28% of score
19 yrs in NPPES registry
- Profile completeness28% of score
100% of core fields populated
- Practice footprint17% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)28% of score
2,987 Medicare services, 2024 (ranked within specialty)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our methodology.
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Test to Examine How Well the Lungs Exchange Gases94729 | 822 | $50 |
| Test to Measure Rate of Airflow94375 | 777 | $37 |
| Test to Determine Lung Volumes Using Sensors94726 | 674 | $49 |
| Test for Exercise-Induced Lung Stress94618 | 246 | $33 |
| Test to Measure Expiratory Airflow and Volume Changes Before and After Medication Administration94060 | 167 | $31 |
| Test to Determine Lung Volumes Using Sensors94726 | 51 | $11 |
| Test to Examine How Well the Lungs Exchange Gases |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 4 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Zolpidem Tartrate | 36 | 19 |
| Methadone Hcl | 18 | — |
| Gabapentin | 14 | — |
| Lorazepam | 11 | — |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means no Part D record, never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Practice location
Mailing address
Registry dates
- Enumerated
- 2007-05-01
- Last updated
- 2012-10-25
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.